VYSOV 50 10

About

Vysov 50 contains Vildagliptin, an oral antidiabetic agent classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for the management of Type 2 Diabetes Mellitus. Its mechanism of action involves the selective inhibition of the DPP-4 enzyme, which is naturally responsible for the rapid breakdown of incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing this degradation, Vildagliptin effectively increases the circulating levels of active incretins. These elevated incretin levels then enhance glucose-dependent insulin secretion from the pancreatic beta cells and simultaneously suppress the inappropriate secretion of glucagon from the alpha cells. This dual action is crucial for improving glycemic control, as it leads to a significant reduction in both fasting and post-meal blood glucose concentrations, making it an effective therapeutic option for patients struggling to achieve their blood sugar targets.

Uses

• Management of Type 2 Diabetes Mellitus.
• To improve glycemic control.
• Used as monotherapy or in combination with other antidiabetics.
• To reduce fasting and post-meal blood sugar levels.

Directions For Use

Take this medication orally, usually once or twice daily, with or without food. Follow your doctor's dosage instructions carefully.

Benefits

• Effectively lowers blood glucose levels.
• Low risk of hypoglycemia when used alone.
• Does not typically cause weight gain.
• Improves both insulin secretion and glucagon suppression.
• Well-tolerated in most patients.
• Helps prevent long-term diabetes complications.

Side Effects

• Nasopharyngitis
• Headache
• Dizziness
• Tremor
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Arthralgia (joint pain)
• Peripheral edema
• Pancreatitis (rare, serious)
• Liver enzyme elevation (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake can affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy due to insufficient data on safety and potential risks to the fetus.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Vildagliptin passes into breast milk and could harm the infant.
• Liver - Vildagliptin is contraindicated in patients with liver impairment (ALT or AST >3x ULN). Liver function should be monitored.
• Kidney - Dose adjustment is necessary in patients with moderate to severe kidney impairment.
• Lung - No specific contraindications or precautions related to lung conditions are typically noted for Vildagliptin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.